Introduction
Despite the advances in chemotherapy over the last few decades, survival is still poor in patients with unresectable metastatic colorectal cancer. Modern chemotherapeutic regimens, including oxaliplatin or irinotecan, with at least one biological agent have extended survival to approximately 2 years. However, tumour response and time of disease control declines significantly after first-line treatment, with a progression-free survival historically ranging between 2 and 4 months after second-line therapy. 1 Our clinic was interested in investigating whether selective internal radiation therapy (SIRT) could play a role in improving the response to second-line chemotherapy by changing the tumour microenvironment − improving the vascular flow and debulking the tumour. There is already some provisional evidence to suggest that SIRT has a favourable effect on the tumour growth. Phase I/II studies have shown that SIRT is associated with a significant debulking of the tumour, as observed by the high response rates (as measured by RECIST), especially in the first-line setting.
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It was considered that SIRT may also allow patients a chemotherapy holiday between first-and second-line treatment. Two key studies from Europe have demonstrated the favourable effects of a treatment holiday in improving tolerability with oxaliplatin in the first-line setting (OPTIMOX study) 6 and treatment response to irinotecan in the second-line setting (FOLFIRI3 study), 7 without diminishing overall survival.
InSIRT
In 2011, the InSIRT study was initiated to investigate whether SIRT administered after first-line therapy could prolong progression-free survival compared with historical controls. Subjects with predominant hepatic metastatic colorectal cancer with evidence of progressive disease following first-line therapy with FOLFOX ± bevacizumab were eligible for inclusion. All patients received SIRT using yttrium-90 radioactive microspheres within 4 weeks of completing first-line chemotherapy. proportion of patients with progression-free survival (PFS) as assessed by RECIST criteria, 6 months after the date of disease progression on first-line therapy. To date, 8 patients have been treated and 9 subjects enrolled (goal 34 subjects) (Fig. 1) . One subject was withdrawn due to progressive lung metastases. Five of nine patients have exceeded the expected PFS of 2.5 months with a historical control. 1 Mean time to progression at the last assessment was 6.7 months (range 0.7-17.3 months) from the date of progression on first-line therapy. 8 There is also some early evidence that the break from chemotherapy to deliver SIRT allows patients to recover from first-line therapy and better tolerate second-line therapy.
Conclusions
In conclusion, SIRT administered between first-and second-line chemotherapy is currently being evaluated as a new approach to improve the duration of response to second-line therapy in selected patients with liver predominant metastatic colorectal cancer. In parallel, investigators will assess changes in blood flow characteristics in the tumour using contrast-enhanced ultrasound, and changes in molecular genetics of the tumour (from tissue samples).
